Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) EBT (2020 - 2025)

Historic EBT for Fulcrum Therapeutics (FULC) over the last 6 years, with Q3 2025 value amounting to -$19.6 million.

  • Fulcrum Therapeutics' EBT rose 968.38% to -$19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.2 million, marking a year-over-year decrease of 31955.56%. This contributed to the annual value of -$9.7 million for FY2024, which is 9000.87% up from last year.
  • As of Q3 2025, Fulcrum Therapeutics' EBT stood at -$19.6 million, which was up 968.38% from -$17.3 million recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' EBT ranged from a high of $55.4 million in Q2 2024 and a low of -$34.1 million during Q2 2022
  • In the last 5 years, Fulcrum Therapeutics' EBT had a median value of -$23.6 million in 2021 and averaged -$18.6 million.
  • As far as peak fluctuations go, Fulcrum Therapeutics' EBT skyrocketed by 33297.73% in 2024, and later plummeted by 13121.51% in 2025.
  • Quarter analysis of 5 years shows Fulcrum Therapeutics' EBT stood at -$23.5 million in 2021, then dropped by 11.29% to -$26.1 million in 2022, then grew by 5.28% to -$24.8 million in 2023, then surged by 33.07% to -$16.6 million in 2024, then fell by 18.27% to -$19.6 million in 2025.
  • Its EBT was -$19.6 million in Q3 2025, compared to -$17.3 million in Q2 2025 and -$16.6 million in Q4 2024.